Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis
Publication date: Available online 11 November 2026 Source: Annals of the Rheumatic Diseases Author(s): Cuong Tran Manh, Christoph Liebel, Aleix Rius Rigau, Bas van der Woning, Piotr Zabrocki, Jörg H.W. Distler, Thuong Trinh-Minh
Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726037799?dgcid=rss_sd_all
Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726037799?dgcid=rss_sd_all
“Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis.” Annals of the Rheumatic Diseases.
@article{article35812,
title = {Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726037799?dgcid=rss_sd_all}
}